NCT00908232 - Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Multiple Myeloma

Interventions

DRUG

Cyclophosphamide

500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles

DRUG

Bortezomib

1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8

DRUG

Dexamethasone

20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8

DRUG

Lenalidomide

10 mg orally daily, days 1-14 for cycles 5 to 8

Trial Locations (42)

Unknown

Bordeaux

Le Mans

Lille

Tours

Duisburg

Essen

Frankfurt (Oder)

Leipzig

München

Mÿnchen

Oldenburg

Ulm

Athens

Pátrai

Budapest

Debrecen

Miskolc

Nyíregyháza

Szeged

Kaunas

Klaipėda

Vilnius Lt

Bialystok

Katowice

Krakow

Lodz

Warsaw

Wroclaw

Belgrade

Kamenitz

Niš

Novi Sad

Barcelona

Madrid

Toledo

Valencia

Ankara

Istanbul

Izmir

Bath

Edinburgh

London